Recognition of CMV-infected fibroblasts after IVS with CMV-poxvirus constructs
. | . | Autologous, % lysis . | . | Allogeneic, % lysis . | . | ||
|---|---|---|---|---|---|---|---|
| UPN . | IVS . | CMV infected . | Untreated . | CMV infected . | Untreated . | ||
| 001 | pp65/pp150-MVA | 40.0 | 3.5 | 41.3 | 2.0 | ||
| 004 | pp65-VV | 20.7 | 0.9 | 22.4 | 3.1 | ||
| 005 | UbRpp65-VV | 48.4 | 10.1 | NA | NA | ||
| 008 | UbRpp65-VV | 31.0 | 2.9 | 27.0 | 6.0 | ||
| 009 | pp65/pp150-MVA | 43.3 | 7.3 | 43.8 | 9.9 | ||
| 009 | IE4-MVA | 28.9 | 0.5 | 32.8 | 2.0 | ||
| 009 | pp65/pp150-MVA + IE4-MVA | 34.5 | 7.2 | 27.4 | 6.0 | ||
| 010 | UbRpp65/pp150-MVA + IE4-MVA | NA | NA | 43.4 | 15.7 | ||
| 010 | UbRIE4-MVA | NA | NA | 30.5 | 3.3 | ||
| 011 | pp65/pp150-MVA + IE4-MVA | 43.8 | 0.9 | 46.0 | 6.4 | ||
| 011 | IE4-MVA | 30.4 | 3.4 | NA | NA | ||
. | . | Autologous, % lysis . | . | Allogeneic, % lysis . | . | ||
|---|---|---|---|---|---|---|---|
| UPN . | IVS . | CMV infected . | Untreated . | CMV infected . | Untreated . | ||
| 001 | pp65/pp150-MVA | 40.0 | 3.5 | 41.3 | 2.0 | ||
| 004 | pp65-VV | 20.7 | 0.9 | 22.4 | 3.1 | ||
| 005 | UbRpp65-VV | 48.4 | 10.1 | NA | NA | ||
| 008 | UbRpp65-VV | 31.0 | 2.9 | 27.0 | 6.0 | ||
| 009 | pp65/pp150-MVA | 43.3 | 7.3 | 43.8 | 9.9 | ||
| 009 | IE4-MVA | 28.9 | 0.5 | 32.8 | 2.0 | ||
| 009 | pp65/pp150-MVA + IE4-MVA | 34.5 | 7.2 | 27.4 | 6.0 | ||
| 010 | UbRpp65/pp150-MVA + IE4-MVA | NA | NA | 43.4 | 15.7 | ||
| 010 | UbRIE4-MVA | NA | NA | 30.5 | 3.3 | ||
| 011 | pp65/pp150-MVA + IE4-MVA | 43.8 | 0.9 | 46.0 | 6.4 | ||
| 011 | IE4-MVA | 30.4 | 3.4 | NA | NA | ||
Fibroblasts were infected with CMV AD169 and used as targets in CRA as described in “Materials and methods.”
Effectors were PBMC stimulated 7 to 12 days with various CMV-poxvirus constructs, as detailed in “Materials and methods.” The percentage killing of autologous (“Autologous”) and HLA A*0201 (or HLA A*0702 for UPNs 005 and 008) allogeneic (“Allogeneic”) fibroblasts, mismatched at least at 2 other HLA loci are shown at E/T 20 for each donor.
NA indicates that either fibroblasts or effector cells were not available for the assay.